Unlocking drug longevity: the crucial role of stability studies

Published: 3-Feb-2025 Featured companies: Almac Group
Regulatory

In the intricate world of drug development, stability studies play a pivotal role by ensuring that both active pharmaceutical ingredients (APIs) and drug products maintain their integrity and efficacy with time

You need to be a subscriber to read this article.
Click here to find out more.

These studies are not just a regulatory requirement but a cornerstone of delivering safe and effective medications to patients.

Understanding the complexities involved in these studies and the critical importance of each step in the process is essential for anyone involved in pharmaceutical development. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

Featured companies

The Almac Group is an established contract development and manufacturing organisation which provides an extensive range of integrated services to the pharmaceutical and biotech...
See more

You may also like

Manufacturing

Almac’s Charnwood facility receives FDA approval for oral dose development and manufacturing

Read more
The facility, which focuses on the manufacture of high potency oral dosage forms, has been approved for use by the FDA

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Forecasting the future of peptide manufacturing: CMC challenges in the GLP-1 era In this article, Torsten Wöhr, Chief Commercial Officer at Bachem, explores the future of peptide CMC manufacturing for GLP-1 therapies, including innovations in sustainable peptide production, purification and compliance
  2. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Extractables and leachables: avoiding compliance bottlenecks to meet regulatory expectations As single-use systems (SUSs) transform the pharmaceutical manufacturing landscape, their growing prevalence has introduced unprecedented opportunities and challenges
  4. Innovative adhesive solution for hygienic, safe and clean bonded packaging Henkel's Technomelt Supra PRO 301 Plus bonds at the high speed of the pharmaceutical industry
  5. AskBio's Parkinson's gene therapy, AB-1005, receives FDA RMAT designation The Bayer subsidiary is currently recruiting for the Phase II REGENERATE-PD trial, which will assess AB-1005's potential in slowing Parkinson's disease progression and improving motor outcomes

Relevant companies

See more

Upcoming event

Interphex

1–3 April 2025 | Conference and Exhibition | New York, US See all

You may also like

Manufacturing

Almac’s Charnwood facility receives FDA approval for oral dose development and manufacturing

The facility, which focuses on the manufacture of high potency oral dosage forms, has been approved for use by the FDA
Manufacturing

Almac completes “outstanding” grade by the KTP

The Innovate UK-funded KTP aimed to embed flow technologies to ensure long term security of supply for key raw materials through development
Manufacturing

Almac Sciences Ireland secures HPRA certification

This additional certification enables Almac to perform biologics testing for the determination of product quality attributes
Regulatory

Almac receives product approval by MHRA and Health Canada

The company’s site provides a range of solutions for blister packs, stickpacks, and kitting
Packaging

Enhancing clinical trial supply with JTM: part I

In a constantly changing world, the pharmaceutical industry is having to adopt its practices to serve the needs of a rapidly growing and ageing population and develop innovative personalised medicines. Almac has responded to these demands with a Just-in-Time Manufacturing solution that fulfils the requirements of a high value, time sensitive clinical supply chain. Dr Kevin Robinson spoke to Natalie Balanovsky, Just-in-Time Manufacturing Solutions Manager, and Mark Rohlfing, Vice President of Operations, to find out more
Regulatory

Almac welcomes confirmation that Northern Ireland will remain aligned with the EU post-Brexit

Move offers Almac clients unique, unfettered and flexible access to both the UK and European markets
Regulatory

Almac Group supports two COVID-19 clinical studies in sub-Saharan Africa

Grant awarded from the COVID-19 Therapeutics Accelerator, an Initiative by the Bill & Melinda Gates Foundation, Wellcome and Mastercard
Subscribe now